WuXi Biologics Revenue Surges, Driven by Complex Biologics Momentum
Event summary
- WuXi Biologics reported record 2025 annual revenue of RMB 21.8 billion, a 16.7% year-over-year increase.
- Adjusted gross profit margin expanded by 340 basis points to 48.8%, driven by favorable business mix and efficiency gains.
- The company’s backlog increased to US$23.7 billion, with US$4.5 billion expected within the next three years.
- New integrated project signings reached a record high of 209, with two-thirds focused on bispecifics and ADCs.
- WuXi Biologics expanded capacity to 200 INDs and 20 BLAs/MAAs annually, supporting a growing pipeline.
The big picture
WuXi Biologics’ strong performance underscores the growing demand for outsourced biologics development and manufacturing, particularly for complex modalities like bispecifics and ADCs. The company’s integrated CRDMO model provides a competitive advantage, allowing it to capture value across the entire drug development lifecycle. The substantial backlog and expansion plans signal continued growth, but also highlight the need for effective execution to manage increasing operational complexity.
What we're watching
- Modality Shift
- The continued dominance of bispecifics and ADCs in WuXi Biologics’ project pipeline suggests a broader industry shift towards complex biologics, potentially impacting demand for traditional mAbs.
- Geopolitical Risk
- The expansion into Qatar, while strategically advantageous, introduces geopolitical risk that could impact operations and supply chain resilience.
- Execution Risk
- The significant expansion of manufacturing capacity (Worcester, Singapore, Qatar) carries execution risk; delays or cost overruns could impact profitability.
Related topics